Results 101 to 110 of about 222,217 (297)

Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy

, 2014
Item does not contain fulltextBACKGROUND AND OBJECTIVES: Cyclophosphamide treatment improves renal survival in patients with idiopathic membranous nephropathy. However, use of cyclophosphamide is associated with cancer.
Hofstra, J.M., Dijk, P.R. van, Brand, J.A. van den, Wetzels, J.F., Jan A.J.G. van den Brand, Jack F.M. Wetzels, Julia M. Hofstra, Peter R. van Dijk   +7 more
core   +1 more source

Ultrasound‐Activated Nanoinhibitors Blocking the Chemo‐Immune Checkpoint to Overcome Chemotherapy‐Induced Immune Resistance

Advanced Science, EarlyView.
A sono‐responsive chemo‐immune checkpoint nanoinhibitor (Sono‐TT8) co‐delivering TPZ chemotherapy and siXkr8 simultaneously kills tumor cells and blocks PS externalization, reversing chemotherapy‐induced immunosuppression and enhancing antitumor immunity. ABSTRACT Breast cancer features an immunosuppressive tumor microenvironment following chemotherapy
Yunfan Liu, Chier Du, Leilei Zhu, Hongjin An, Shengzhe Hou, Yi Lan, Xuemei Tang, Min Xu, Peng Luo, Hua Teng, Hao Yang, Xun Guo, Jianli Ren, Zhiyi Zhou   +13 more
wiley   +1 more source

Bone marrow mesenchymal stem cell repair of cyclophosphamide-induced ovarian insufficiency in a mouse model

, 2017
Ahmed Badawy,1 Mohamed A Sobh,2 Mohamed Ahdy,3 Mohamed Sayed Abdelhafez1 1Department of Obstetrics and Gynecology, 2Department of Internal Medicine, 3Department of Clinical Pharmacology, Mansoura University, Mansoura, Egypt Objective: Attempting in ...
Sobh MA, Badawy A, Ahdy M, Abdelhafez MS
core  

Effect of cytostatic drug presence on extracellular polymeric substances formation in municipal wastewater treated by membrane bioreactor [PDF]

, 2010
The effect of the cyclophosphamide and its mean metabolites on extracellular polymeric substances (EPS) formation was investigated. Two lab-scale membrane bioreactors were followed in parallel (one with the cytostatic drugs, the second without ...
Delgado, L.F., Avella, Catalina, Delgado, Luis Fernando, Avella, A.C., Görner, Tatiana, Albasi, Claire, de Donato, Ph., Galmiche, M., Görner, T., De Donato, Philippe, T. Görner, C. Albasi, L.F. Delgado, M. Galmiche, Ph. de Donato, A.C. Avella   +15 more
core   +1 more source

Alkylating Agent–Induced FANCL Impairment Damages Pulmonary Arterial, Venous, and Microvascular Endothelial Cells and Predisposes to PAH/PVOD

Advanced Science, EarlyView.
This study establishes a novel cisplatin‐induced rat model of PAH/PVOD and identifies a conserved mechanistic axis—FANCL impairment, DNA damage accumulation, and endothelial dysfunction—triggered by cisplatin or mitomycin C across pulmonary arteries, veins, and microvessels.
Shiyun Liu, Yufei Sun, Xinlei Wu, Haixia Chen, Shaocong Mo, Zichong Li, Yiwei Gong, Xiaoqian Shan, Yuanqi Li, Yaru Guan, Junqi Zhu, Han Yan, Min Du, Feng Wei, Peixin Ou, Ziyi Wang, Chenting Zhang, Lei Xu, Wenju Lu, Jian Wang, Kai Yang   +20 more
wiley   +1 more source

Use of testosterone to prevent cyclophosphamide-induced azoospermia

, 1997
BACKGROUND: Prepubertal patients receiving chemotherapy are relatively resistant to cyclophosphamide-induced germinal cell alterations. OBJECTIVE: To study the possible protective effect of testosterone used to inhibit germinal cell activity in ...
MASALA, Antonio Giovanni Emilio, Faedda R, Ivaldi R, Alagna S, Lai E, Chiarelli G, SATTA, Andrea Ercole, Taras MS, Bartoli E., Rovasio PP   +9 more
core  

Antitumor Effect of Interleukin 2 and Cyclophosphamide Administration [PDF]

, 2017
application/pdfDepartmental Bulletin PaperEL4-bearing C57BL mice were treated cyclophosphamide and/or with IL2. Mice treated with cyclophosphamide alone survived significantly longer than nontreated mice, while IL2-treated mice did not. Mice treated with
Kurashige, Satonori, 2346, 2345, 2344, Akuzawa, Yuki, Kodama, Kazue   +5 more
core  

Dosage of cyclophosphamide in the control group.

, 2014
Dosage of cyclophosphamide in the control group.
Łukasz Adaszek (599076), Monika Michałowska (599074), Wojciech Łopuszyński (599077), Zbigniew Grądzki (599078), Stanislaw Winiarczyk (599075), Walter H. Günzburg (315731), Brian Salmons (77633)   +6 more
core   +1 more source

ZMIZ2–DUX4–LGR5 Signaling Axis Maintains Stemness Properties and Facilitates Docetaxel Resistance in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
This study identifies ZMIZ2 as a therapeutic target for docetaxel‐resistant triple‐negative breast cancer, sustaining cancer stemness‐associated properties and docetaxel resistance. ZMIZ2 upregulation enhances DUX4‐mediated LGR5 activation through the SWI/SNF components BRG1 and BAF57.
Xueting Gan, Shulei Sun, Ran Hu, Yuheng Feng, Xinhao Wu, Fangqi Liu, Xuyong Lin, Xiupeng Zhang, Xuezhu Rong, Qiang Han   +9 more
wiley   +1 more source

Chromosomal Abnormalities, Drug Sensitivity and Resistance in Hematological Malignancies: A Comprehensive Overview by the Francophone Group of Hematological Cytogenetics (GFCH)

American Journal of Hematology, EarlyView.
ABSTRACT Chromosomal abnormalities have a major clinical impact on hematological malignancies, particularly with regard to treatment strategies. To preserve and consolidate fundamental knowledge in this rapidly evolving field, the Francophone Group of Hematological Cytogenetics (Groupe Francophone de Cytogénétique Hématologique, GFCH) conducted a ...
Florence Nguyen‐Khac, Audrey Bidet, Elise Chapiro, Nathalie Douet‐Guilbert, Jean‐Baptiste Gaillard, Nada Assaf, Nathalie Auger, Hend Chaker, Jasmine Chauzeix, Inge Govaerts, Hippolyte Guérineau, Christine Lefebvre, Pauline Roynard, Hélène Guermouche, Lucienne Michaux, Marie‐Bérengère Troadec, Lauren Véronèse   +16 more
wiley   +1 more source